Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC
June 22, 2022
Pasithea Therapeutics Corp. acquired all outstanding equity interests in Alpha-5 Integrin, LLC, a preclinical biotechnology company developing a monoclonal antibody targeting α5 integrin for ALS and other neuroinflammatory disorders. The transaction was valued at $3.75 million and was paid primarily in Pasithea common stock (3,260,870 shares) plus warrants; an entity controlled by Paul B. Manning was Alpha-5's majority owner prior to the deal.
- Buyers
- Pasithea Therapeutics Corp.
- Targets
- Alpha-5 Integrin, LLC
- Sellers
- An entity controlled by Paul B. Manning
- Industry
- Biotechnology
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Pasithea Therapeutics Acquires AlloMek Therapeutics
October 11, 2022
Biotechnology
Pasithea Therapeutics Corp. (Nasdaq: KTTA) acquired AlloMek Therapeutics, LLC, obtaining the preclinical MEK 1/2 inhibitor CIP-137401 to expand its CNS-focused drug-development pipeline. The deal closed on October 11, 2022 and included $1.05 million in upfront cash, issuance of restricted stock and warrants, plus potential clinical/regulatory milestones and royalties.
-
AbbVie Completes $1.4B Acquisition of Aliada Therapeutics
December 11, 2024
Biotechnology
AbbVie completed its $1.4 billion cash acquisition of RA Capital Management portfolio company Aliada Therapeutics. The deal adds ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in Phase 1 for Alzheimer’s disease, and Aliada’s blood-brain barrier (BBB)-crossing MODEL delivery platform to AbbVie’s neuroscience pipeline.
-
Sorrento Therapeutics Acquires ACEA Therapeutics
June 1, 2021
Biotechnology
Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.
-
Arcline Investment Management Acquires Polypeptide Therapeutic Solutions (PTS)
April 27, 2021
Biotechnology
Arcline Investment Management, a growth-oriented private equity firm, has acquired Polypeptide Therapeutic Solutions, S.L. (PTS) from Columbus Venture Partners. PTS is a Valencia-based GMP CDMO specializing in polyamino-acid (PAA) nanoparticle encapsulation and related drug-delivery services; Arcline plans to scale GMP production and expand the company's technology portfolio to support mRNA, gene/cell therapies, biologics and vaccines.
-
Innoviva Acquires Entasis Therapeutics
May 23, 2022
Biotechnology
Innoviva agreed to acquire the remaining shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis equity at about $113 million on a fully diluted basis. Innoviva completed the acquisition in July 2022, making Entasis a wholly owned subsidiary.
-
Eilean Therapeutics Acquires Ness Therapeutics
March 4, 2024
Biotechnology
Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.